MENU
CLLS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Cellectis SA (CLLS) Earnings Date & Reports

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

CLLS is expected to report earnings to fall 2,900.00% to -28 cents per share on March 11

Cellectis SA CLLS Stock Earnings Reports
Q4'25
Est.
$-0.28
Q3'25
Beat
by $0.24
Q2'25
Missed
by $0.02
Q1'25
Beat
by $0.07
Q4'24
Missed
by $0.07
The last earnings report on November 07 showed earnings per share of 0 cents, beating the estimate of -23 cents. With 63.05K shares outstanding, the current market capitalization sits at 379.70M.
View a ticker or compare two or three
CLLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CLLS showed earnings on November 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com